Zobrazeno 1 - 10
of 138
pro vyhledávání: '"autologous t cells"'
Autor:
Nicolas Gestermann, Damien Saugy, Christophe Martignier, Laure Tillé, Silvia A. Fuertes Marraco, Markus Zettl, Iñigo Tirapu, Daniel E. Speiser, Grégory Verdeil
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Despite the success of immunotherapy using checkpoint blockade, many patients with solid tumors remain refractory to these treatments. In human cancer, the experimental options to investigate the specific effects of antibodies blocking inhibitory rec
Externí odkaz:
https://doaj.org/article/1305c4c5a45641c5a2eae2d6e2c5c1ed
Autor:
Yao Wang, Meixia Chen, Zhiqiang Wu, Chuan Tong, Hanren Dai, Yelei Guo, Yang Liu, Jianhua Huang, Haiyan Lv, Can Luo, Kai-chao Feng, Qing-ming Yang, Xiao-lei Li, Weidong Han
Publikováno v:
OncoImmunology, Vol 7, Iss 7 (2018)
Expressed by cancer stem cells of various epithelial cell origins, CD133 is an attractive therapeutic target for cancers. Autologous chimeric antigen receptor-modified T-cell directed CD133 (CART-133) was first tested in this trial. The anti-tumor sp
Externí odkaz:
https://doaj.org/article/f3e7c9850ad74bd1afb8b2aa4cd9e521
Publikováno v:
British Journal of Haematology. 197:28-40
Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapy in haematological malignancies. However, the currently approved products are generated from autologous T cells that require orchestration of several logistically complex step
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60e8b3b080d6d2ced41d7273627305d2
https://doi.org/10.1111/bjh.17904
https://doi.org/10.1111/bjh.17904
Autor:
Lionel Karlin
Publikováno v:
Hématologie. 27:5-12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a6a52e7e92d03b81e926c91d81fe23b
https://doi.org/10.1684/hma.2021.1637
https://doi.org/10.1684/hma.2021.1637
Publikováno v:
Cancer J
Immune checkpoint inhibition has vastly improved the treatment of solid tumors, but most patients do not experience durable clinical benefit, so novel immunotherapeutic approaches are needed. Autologous T cells genetically engineered to express chime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70b68053e2413109994a54ddec31c827
https://doi.org/10.1097/ppo.0000000000000516
https://doi.org/10.1097/ppo.0000000000000516
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jared J. Gartner, Yong-Chen Lu, Paul F. Robbins, Steven A. Rosenberg, Frank J. Lowery, Todd D. Prickett, Zhili Zheng
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundRecognition of neoantigens by T cells plays a major role in cancer immunotherapy. Identification of neoantigen-specific T-cell receptors (TCRs) has become a critical research tool for studying T cell-mediated responses after immunotherapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ac20edb9c0d58f31b51aa6a9d3963df
https://jitc.bmj.com/content/9/7/e002595.full
https://jitc.bmj.com/content/9/7/e002595.full
Autor:
Simon F. Lacey, Joseph A. Fraietta
Publikováno v:
Trends in Molecular Medicine. 26:713-715
The clinical application of CRISPR-Cas9 gene editing has been eagerly awaited since the first description of the technique in 2013. Lu and colleagues now describe the treatment of 12 patients with nonsmall-cell lung cancer (NSCLC) with PD-1 gene-edit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa9f9e7ee31b2278c934c056ee434200
https://doi.org/10.1016/j.molmed.2020.06.001
https://doi.org/10.1016/j.molmed.2020.06.001
Manufacturing of genetically modified autologous T cells: key considerations for process development
Autor:
Ali Mohamed, Mamta Kalra
Publikováno v:
Cell and Gene Therapy Insights. 5:351-358
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::837e19713e629046e20687fa019e9388
https://doi.org/10.18609/cgti.2019.039
https://doi.org/10.18609/cgti.2019.039
Autor:
L. Cutmore, John Marshall
Publikováno v:
Cancers, Vol 13, Iss 1926, p 1926 (2021)
Cancers
Cancers
Simple Summary CAR T cells are a type of immunotherapy whereby a patient’s own cells are genetically modified to recognise and kill the patient’s own cancer cells. Currently, each patient has CAR T cells made from their own blood cells. This type
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e46c7434a34a578ae4dcb3f7faeec3c0
https://www.mdpi.com/2072-6694/13/8/1926
https://www.mdpi.com/2072-6694/13/8/1926